Sanofi’s Toujeo – a follow-up to its long-acting insulin drug Lantus – has underperformed commercially since launch but the company hopes new data could help it gather momentum. The French ...

Sanofi's follow-up product to its insulin blockbuster Lantus has been approved in Europe. Toujeo (insulin glargine [rDNA origin]) has been approved for the treatment of type 1 and type 2 diabetes ...

Attorney General Aaron M. Frey announced a settlement agreement with Sanofi-Aventis U.S. LLC after scrutiny over the company’s pricing of insulin products.

There is good news for Mainers who rely on insulin according to our media partners WMTW. Maine Attorney General Aaron Frey announced a settlement agreement Tuesday with Sanofi-Aventis U.S. following ...

Toujeo, which provides a steady insulin release over 24 hours via a once-daily injection, has become an essential solution for individuals with type 1 and type 2 diabetes. Its efficacy in ...